- November 9, 2012
- Posted by: Spotscreen
- Category: News
No Comments
Yervoy, the melanoma drug developed in the US, is said to be responsible for significantly reducing tumors and extending life expectancy in terminally ill melanoma patients.
Despite these results, the chance that most melanoma sufferers in Australia will get access to this drug is very slim. With a price tag of $120,000 per treatment the drug is financially not an option for many. Read More Here